RxDoctor Payments Data

Marshall Taylor, MD

Nephrology · Greenville, NCNPI 1710989934

Payments from drug & device makers

$1,787in general payments, 2019–2025

Across 81 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$535
  • Amgen$275
  • Nxstage Medical, Inc.$204
  • Vifor Pharma, Inc.$137
  • Otsuka America Pharmaceutical, Inc.$91
  • OPKO Pharmaceuticals, LLC$79
  • plus $467 from 17 others

What the payments were for

  • Food & beverage$1,75998%
  • Education$282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,787 in reported general payments places this provider in the 50th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$117,855
Medicare patients
197
Services billed
2,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuryxiaFerric Citrate19$47,842
FarxigaDapagliflozin Propanediol52$41,090
RayaldeeCalcifediol22$28,252
VeltassaPatiromer Calcium Sorbitex30$22,932
JardianceEmpagliflozin23$17,699
Sevelamer Carbonate72$15,122
KerendiaFinerenone12$8,720
Cinacalcet Hcl23$4,385
Bumetanide56$1,889
Calcium Acetate20$1,791
Losartan Potassium80$1,162
Eplerenone26$1,102
Allopurinol65$818
Amlodipine Besylate128$770
Potassium Chloride27$566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$61$47,84219 claims
AstraZenecaFarxiga$535$41,09052 claims
OPKO Pharmaceuticals, LLCRayaldee$79$28,25222 claims
BayerKerendia$15$8,72012 claims
ANI Pharmaceuticals, Inc.Valsartan$20$37131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 366 nephrology providers in North Carolina.

Other nephrology in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →